##### Table of Contents



UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
  Form 10-Q/A
  (Mark One) þ
    
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended September 30, 2004Oro
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from    to    .
 Commission File Number 0-28402
 Aradigm Corporation (Exact name of registrant as specified in its charter)
 California
    
    94-3133088(State or other jurisdiction of
    
    (I.R.S. Employerincorporation or organization)
    
    Identification No.)
 3929 Point Eden Way
Hayward, CA 94545  (Address of principal executive offices including zip code)  (510) 265-9000  (Registrants telephone number, including area code)
 þ o
 Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act).   Yes o  No þ Indicate the number of shares outstanding of each of the issuers classes
of common stock, as of the latest practicable date. Common Stock, no par value
    
    63,962,335(Class)
    
    (Outstanding at
October 31, 2004)




---








ARADIGM CORPORATION
INDEX

|                           |  |          |   | 
|-------------------------- |  | -------- | - | 
|                           |  | Page
No.
|PART
II. OTHER INFORMATION |  |          | 2 | 
|ITEM 6. Exhibits           |  |          | 2 | 
|Signatures                 |  |          | 3 | 
|Index to Exhibits          |  |          | 4 | 
|EXHIBIT 10.29             
|EXHIBIT 31.1              
|EXHIBIT 31.2              



1



---



##### Table of Contents



EXPLANATORY

NOTE This amended Quarterly Report on Form 10-Q/A is being filed
solely for the purpose of re-filing Exhibit 10.29 in connection
with an application for confidential treatment. Exhibit 10.29 was
originally filed with Aradigms Quarterly Report on
Form 10-Q on November 15, 2004. The redactions to
Exhibit 10.29 have been amended in accordance with a revised
application for confidential treatment filed separately by Aradigm
with the Securities and Exchange Commission. Aradigm has made no
further changes to the previously filed quarterly report. 
 PART II. OTHER
INFORMATION 
 Item 6.
Exhibits (a) Exhibits  10.29*

Restructuring Agreement, dated as of
September 28, 2004, among Aradigm Corporation, Novo Nordisk A/S
and Novo Nordisk Delivery Technologies, Inc.31.1

Certification by Chief Executive
Officer pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.31.2

Certification by Chief Financial
Officer pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.32.1

Certification by Chief Executive
Officer and Chief Financial Officer pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002. * The Company has sought confidential
treatment for portions of the referenced exhibit.  Previously filed. 2




---



##### Table of Contents








SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

| |                                                   |  |  | 
| | ------------------------------------------------- |  |  | 
| | ARADIGM CORPORATION
(Registrant)                  | 
| |                                                   | 
| | /s/ V. Bryan LawlisV. Bryan Lawlis                | 
| | President and Chief Executive Officer             | 
|
| |                                                   | 
| |                                                   | 
| | /s/ Thomas C. ChestermanThomas C. Chesterman      | 
| | Senior Vice President and Chief Financial Officer | 
|

Dated: December 22, 2004

3



---



##### Table of Contents



INDEX TO EXHIBITS ExhibitNumber
    
    Description10.29*
    
    Restructuring Agreement, dated as of September 28, 2004,
among Aradigm Corporation, Novo Nordisk A/S and Novo
Nordisk Delivery Technologies, Inc.31.1
    
    Certification by Chief Executive Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.31.2
    
    Certification by Chief Financial Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.32.1
    
    Certification by Chief Executive Officer and Chief
Financial Officer pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
 * The Company has sought confidential treatment for portions of the referenced exhibit.  Previously filed. 4